RU2016126503A - Аналоги кортистатина, их синтез и применения - Google Patents

Аналоги кортистатина, их синтез и применения Download PDF

Info

Publication number
RU2016126503A
RU2016126503A RU2016126503A RU2016126503A RU2016126503A RU 2016126503 A RU2016126503 A RU 2016126503A RU 2016126503 A RU2016126503 A RU 2016126503A RU 2016126503 A RU2016126503 A RU 2016126503A RU 2016126503 A RU2016126503 A RU 2016126503A
Authority
RU
Russia
Prior art keywords
optionally substituted
attached
compound
heterocyclyl
optionally
Prior art date
Application number
RU2016126503A
Other languages
English (en)
Russian (ru)
Other versions
RU2016126503A3 (2
Inventor
Мэттью Д. Шаир
Йурген Рамхартер
Генри Эфрем Пелиш
Брайн Бор-Йен Лиау
Джае Янг Ахн
Original Assignee
Президент Энд Феллоус Оф Гарвард Колледж
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Президент Энд Феллоус Оф Гарвард Колледж filed Critical Президент Энд Феллоус Оф Гарвард Колледж
Publication of RU2016126503A publication Critical patent/RU2016126503A/ru
Publication of RU2016126503A3 publication Critical patent/RU2016126503A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2016126503A 2013-12-24 2014-12-24 Аналоги кортистатина, их синтез и применения RU2016126503A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361920674P 2013-12-24 2013-12-24
US61/920,674 2013-12-24
US201461935240P 2014-02-03 2014-02-03
US61/935,240 2014-02-03
US201461993329P 2014-05-15 2014-05-15
US61/993,329 2014-05-15
PCT/US2014/072365 WO2015100420A1 (en) 2013-12-24 2014-12-24 Cortistatin analogues and syntheses and uses thereof

Publications (2)

Publication Number Publication Date
RU2016126503A true RU2016126503A (ru) 2018-01-30
RU2016126503A3 RU2016126503A3 (2) 2018-07-17

Family

ID=52350382

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016126503A RU2016126503A (ru) 2013-12-24 2014-12-24 Аналоги кортистатина, их синтез и применения

Country Status (30)

Country Link
US (3) US9994582B2 (2)
EP (2) EP3505521A1 (2)
JP (2) JP6494631B2 (2)
KR (1) KR20160101162A (2)
CN (2) CN106103452B (2)
AP (1) AP2016009324A0 (2)
AU (2) AU2014369834B2 (2)
BR (1) BR112016014760A2 (2)
CA (1) CA2934819A1 (2)
CL (1) CL2016001631A1 (2)
CR (1) CR20160291A (2)
DO (1) DOP2016000158A (2)
EA (2) EA030907B1 (2)
EC (1) ECSP16062174A (2)
ES (1) ES2709480T3 (2)
GT (1) GT201600135A (2)
IL (1) IL246390A0 (2)
MD (1) MD20160089A2 (2)
MX (1) MX361652B (2)
MY (1) MY180383A (2)
NI (1) NI201600089A (2)
PE (1) PE20161405A1 (2)
PH (1) PH12016501258A1 (2)
RU (1) RU2016126503A (2)
SA (1) SA516371410B1 (2)
SG (2) SG10201808151RA (2)
SV (1) SV2016005234A (2)
TN (1) TN2016000240A1 (2)
WO (1) WO2015100420A1 (2)
ZA (1) ZA201603894B (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014369834B2 (en) 2013-12-24 2018-12-20 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
RU2017142394A (ru) * 2015-05-08 2019-06-10 Президент Энд Феллоус Оф Гарвард Колледж Целевой отбор пациентов для лечения производными кортистатина
WO2016182932A1 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
WO2017112823A1 (en) * 2015-12-23 2017-06-29 President And Fellows Of Harvard College Targeted selection of patients for treatment with specific cortistatin derivatives
WO2017112815A1 (en) * 2015-12-23 2017-06-29 President And Fellows Of Harvard College Cortistatin analogs and uses thereof
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US20190062340A1 (en) * 2016-02-19 2019-02-28 President And Fellows Of Harward College Cortistatin analogs
US11285144B2 (en) 2016-08-03 2022-03-29 The Broad Institute, Inc. Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity
CN114921468A (zh) 2017-01-30 2022-08-19 国立大学法人京都大学 新型化合物以及调节性t细胞的制造方法
CN107028956A (zh) * 2017-03-06 2017-08-11 刘杰 一种治疗经期抑郁症的药物组合物
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
CN113677341B (zh) * 2019-02-01 2024-07-05 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法
EP4065111A4 (en) 2019-11-26 2023-09-20 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of cdk8 and cdk19
AU2022349176A1 (en) 2021-09-27 2024-04-11 Kyoto University Method for producing t cell
MX2024006370A (es) 2021-11-24 2024-08-19 Regcell Co Ltd Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t.
US20250018033A1 (en) 2021-11-24 2025-01-16 Regcell Co., Ltd. Human inducibility controllable t-cell and method for preparing same
CN119256076A (zh) 2022-03-23 2025-01-03 国立大学法人京都大学 用于产生调节性t细胞的方法
EP4600352A1 (en) 2022-09-26 2025-08-13 Kyoto University T cell production method
EP4596684A1 (en) 2022-09-26 2025-08-06 Regcell Co., Ltd. Induced regulatory t cells containing chimeric antigen receptor (car)
KR20250140618A (ko) 2023-02-08 2025-09-25 레그셀 가부시키가이샤 천포창을 치료 또는 예방하기 위한 의약 조성물
JPWO2024204553A1 (2) 2023-03-29 2024-10-03

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886589A (en) 1957-08-05 1959-05-12 Merck & Co Inc 8-methyl-5-oxyphenyl hexahydroindan compounds
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5185152A (en) 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
IL105050A0 (en) 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5554187A (en) 1995-08-18 1996-09-10 Rizzo, Iii; Joseph Medication dispensing intra-ocular lens system
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6074872A (en) 1996-05-15 2000-06-13 The Scripps Research Institute Cortistatin: nucleic acids that encode these neuropeptides
ZA978537B (en) 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
AU5902398A (en) 1996-12-31 1998-07-31 Human Genome Sciences, Inc. Cortistatin polypeptides
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
CN1187364C (zh) 1999-04-30 2005-02-02 亚其发展公司 类固醇衍生物
PT1955700E (pt) 1999-09-30 2011-05-04 Harbor Biosciences Inc Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
EP1235851B1 (en) 1999-10-13 2006-05-31 Johns Hopkins University School of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
JP2003512474A (ja) 1999-10-25 2003-04-02 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 血液細胞欠乏症の治療処置
CN1827621A (zh) * 2000-03-31 2006-09-06 萨诺化学药物股份公司 雪花胺的新衍生物和类似物
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
ITMI20011445A1 (it) 2001-07-06 2003-01-06 Europ Geie Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita
WO2003063787A2 (en) 2002-01-30 2003-08-07 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
WO2004058795A1 (en) 2002-12-24 2004-07-15 The University Of British Columbia Angiogenic compounds and uses thereof
PL378577A1 (pl) 2003-03-24 2006-05-02 Sterix Limited Pochodne estrogenu jako inhibitory sulfatazy steroidowej
EP1633367A2 (en) 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogenic agents
DE602004025946D1 (de) * 2003-07-24 2010-04-22 Merck Sharp & Dohme Antibiotische verbindung
US20070004689A1 (en) 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
GB0421106D0 (en) 2004-09-22 2004-10-27 Sterix Ltd Compound
AU2006218711B2 (en) 2005-03-02 2010-11-11 University Of Maryland, Baltimore Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US20090023666A1 (en) 2006-01-09 2009-01-22 BTG plc Modulators of Hypoxia Inducible Factor-1 and Related Uses
WO2007082980A1 (es) 2006-01-23 2007-07-26 Consejo Superior De Investigaciones Científicas Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina
WO2007103162A2 (en) 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
AU2007284994B2 (en) * 2006-05-09 2010-04-22 Merck Sharp & Dohme Corp. Substituted spirocyclic CGRP receptor antagonists
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
WO2008064425A1 (en) 2006-11-30 2008-06-05 Solbec Pharmaceuticals Limited Glycoalkaloid and chemotherapeutic agent combinations and various uses thereof
WO2008079028A1 (en) 2006-12-22 2008-07-03 Industrial Research Limited Azetidine analogues of nucleosidase and phosphorylase inhibitors
RU2009137012A (ru) 2007-03-07 2011-04-20 Инфинити Дискавери, Инк. (Us) Аналоги циклопаминлактама и способы их применения
EP2205074A4 (en) * 2007-10-04 2013-07-31 Harvard College MOENOMYCIN ANALOGUE, SYNTHESIS PROCESS AND USE
WO2009137337A1 (en) * 2008-05-05 2009-11-12 The Scripps Research Institute STEREOSELECTIVE SYNTHESIS OF 17-α -AND 17-β -ARYL STEROIDAL COMPOUNDS
US20110190323A1 (en) * 2008-08-28 2011-08-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses thereof
EP2421882A4 (en) 2009-04-22 2013-05-08 Harvard College ANGIOGENESIS INHIBITORS
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
MX2012013378A (es) 2010-05-20 2013-01-24 Hoffmann La Roche Derivados de pirrolo [2, 3-b] pirazina-7-carboxamida y sus uso como inhibidores de cinasa janus (jak) y cinasa tirosina del brazo (syk).
US8791263B2 (en) 2010-09-17 2014-07-29 Osaka University Cortistatin A analog and use thereof
EP2663574A4 (en) 2011-01-10 2014-12-17 Scripps Research Inst RETRO VIRUS REPLICATION INHIBITORS
KR20150023223A (ko) 2012-02-02 2015-03-05 세넥스 바이오테크놀러지 인코포레이티드 Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도
WO2013122609A1 (en) 2012-02-17 2013-08-22 Genentech, Inc. Methods of using cdk8 antagonists
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
WO2014134169A1 (en) 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
WO2014199377A1 (en) 2013-06-10 2014-12-18 Yeda Research And Development Co. Ltd. Compositions and methods for treating a hematological malignancy associated with an altered runx1 activity or expression
EP3046933B1 (en) 2013-09-18 2019-02-27 BCN Peptides, S.A. Cortistatin analogues for the treatment of inflammatory and/or immune diseases
AU2014369834B2 (en) * 2013-12-24 2018-12-20 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof

Also Published As

Publication number Publication date
US20190185484A1 (en) 2019-06-20
AU2014369834A1 (en) 2016-06-23
US9994582B2 (en) 2018-06-12
MX361652B (es) 2018-12-13
GT201600135A (es) 2018-11-27
SA516371410B1 (ar) 2019-02-13
IL246390A0 (en) 2016-08-31
ZA201603894B (en) 2018-08-29
NI201600089A (es) 2016-08-18
CL2016001631A1 (es) 2017-02-24
CN106103452A (zh) 2016-11-09
US20170029435A1 (en) 2017-02-02
PH12016501258A1 (en) 2016-08-15
BR112016014760A2 (pt) 2017-12-12
JP2017509586A (ja) 2017-04-06
AP2016009324A0 (en) 2016-07-31
DOP2016000158A (es) 2016-10-16
SG10201808151RA (en) 2018-10-30
EP3505521A1 (en) 2019-07-03
PE20161405A1 (es) 2017-01-18
CN110183461A (zh) 2019-08-30
ECSP16062174A (es) 2018-12-31
MY180383A (en) 2020-11-28
US10508121B2 (en) 2019-12-17
JP2019108367A (ja) 2019-07-04
US20180319814A1 (en) 2018-11-08
MX2016008436A (es) 2016-12-16
WO2015100420A1 (en) 2015-07-02
AU2019201888A1 (en) 2019-04-11
EA201891279A1 (ru) 2019-01-31
SG11201605178WA (en) 2016-07-28
JP6494631B2 (ja) 2019-04-03
TN2016000240A1 (en) 2017-10-06
EP3087080B1 (en) 2018-11-28
KR20160101162A (ko) 2016-08-24
EP3087080A1 (en) 2016-11-02
CA2934819A1 (en) 2015-07-02
ES2709480T3 (es) 2019-04-16
RU2016126503A3 (2) 2018-07-17
MD20160089A2 (ro) 2016-12-31
AU2014369834B2 (en) 2018-12-20
EA201691167A1 (ru) 2016-11-30
US10273241B2 (en) 2019-04-30
CN106103452B (zh) 2019-05-21
CR20160291A (es) 2017-02-24
SV2016005234A (es) 2018-12-14
EA030907B1 (ru) 2018-10-31

Similar Documents

Publication Publication Date Title
RU2016126503A (ru) Аналоги кортистатина, их синтез и применения
JP2017509586A5 (2)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
JP2014511892A5 (2)
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
JP2016513130A5 (2)
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
RU2017112048A (ru) Синергистические комбинации ауристана
RU2018119173A (ru) Производное бензофурана, способ его получения и его применение в медицине
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
RU2018128334A (ru) Ингибиторы индоламин-2,3-диоксигеназы (ido)
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
RU2017104856A (ru) Функционализированные и замещенные индолы в качестве противораковых средств
RU2018106483A (ru) Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
JP2015522650A5 (2)
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
RU2013136861A (ru) Новое производное индола или индазола или его соль
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
RU2013136895A (ru) Новое бициклическое соединение или его соль
RU2015141592A (ru) АРИЛ-СУЛЬФАМИДЫ И СУЛЬФАМАТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190822